{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:10:39Z","timestamp":1791612639168,"version":"4.3.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary membranous nephropathy (MN) is a frequent cause of nephrotic syndrome (NS) in adults. In untreated patients, the outcome is variable, with one-third of the patients entering remission while the remaining ones show persisting proteinuria or progression to end-stage renal disease. Randomized clinical trials reported the efficacy of a 6-month regimen alternating intravenous and oral glucocorticoids with an alkylating agent every other month. The potential side effects of this regimen were limited by the fact that the use of glucocorticoids and alkylating agent did not exceed 3\u2009months each. Two randomized trials with follow-ups (FU) up to 10\u2009years provided assurance about the long-term efficacy and safety of this cyclical therapy. Calcineurin inhibitors have also been used successfully. However, in most responders, NS relapsed after the drug was withdrawn. Conflicting results have been reported with mycophenolate salts and adrenocorticotropic hormone. Observational studies reported good results with rituximab (RTX). Two controlled trials demonstrated the superiority of RTX over antiproteinuric therapy alone and cyclosporine. However, the FUs were relatively short and no randomized trial has been published against cyclical therapy. The available results, together with the discovery that most patients with MN have circulating antibodies against the phospholipase A2 receptor 1, support the use of cytotoxic drugs or RTX in MN. It is difficult to choose between these two different treatments. RTX is easier to use, but the FUs of the available studies are short, thus doubts remain about the long-term risk of relapses and the safety of repeated administrations of RTX.<\/jats:p>","DOI":"10.1093\/ndt\/gfaa014","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T20:10:07Z","timestamp":1578687007000},"page":"768-773","source":"Crossref","is-referenced-by-count":10,"title":["The evolution of the therapeutic approach to membranous nephropathy"],"prefix":"10.1093","volume":"36","author":[{"given":"Claudio","family":"Ponticelli","sequence":"first","affiliation":[{"name":"Retired, Nephrology Unit, Ospedale Maggiore, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Passerini","family":"Patrizia","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Renal Transplant Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Independent Researcher, Como, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Past Director, Department of Nephrology and Dialysis, ASST Lecco, Lecco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"2021042619265242000_gfaa014-B1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B3","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/ndt\/gfv435","article-title":"Long-term outcomes of persistent disease and relapse in primary membranous nephropathy","volume":"31","author":"Kanigicherla","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2021042619265242000_gfaa014-B4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ki.1974.129","article-title":"Controlled trial of cyclophosphamide in idiopathic membranous nephropathy","volume":"6","author":"Donadio","year":"1974","journal-title":"Kidney Int"},{"key":"2021042619265242000_gfaa014-B5","first-page":"655","article-title":"Traitement par le chlorambucil et l\u2019azathioprine dans les glom\u00e9rulonephrites primitives: resultats d\u2019une \u00e9tude control\u00e9e","volume":"81","author":"Lagrue","year":"1975","journal-title":"J Urol N\u00e9phrol"},{"key":"2021042619265242000_gfaa014-B6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM197912133012401","article-title":"A controlled study of short-term prednisone treatment in adults with membranous nephropathy","volume":"301","year":"1979","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/oxfordjournals.qjmed.a068422","article-title":"The Medical Research Council trial of short-term high-dose, alternate-day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults","volume":"74","author":"Cameron","year":"1990","journal-title":"Q J Med"},{"key":"2021042619265242000_gfaa014-B8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1056\/NEJM198901263200403","article-title":"A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy","volume":"320","author":"Cattran","year":"1989","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.280.6215.685","article-title":"Intravenous methylprednisolone in minimal change nephrotic syndrome","volume":"280","author":"Ponticelli","year":"1980","journal-title":"Br Med J"},{"key":"2021042619265242000_gfaa014-B10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/IAI.38.1.122-126.1982","article-title":"Methylprednisolone inhibits the alternative and amplification pathways of complement","volume":"38","author":"Weiler","year":"1982","journal-title":"Infect Immun"},{"key":"2021042619265242000_gfaa014-B11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2215\/CJN.12991117","article-title":"Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls","volume":"13","author":"Ponticelli","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B12","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"310","author":"Ponticelli","year":"1984","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199208273270904","article-title":"Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group","volume":"327","author":"Ponticelli","year":"1992","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B16","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"2021042619265242000_gfaa014-B17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B18","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000364782","article-title":"Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies","volume":"40","author":"Leeaphorn","year":"2014","journal-title":"Am J Nephrol"},{"key":"2021042619265242000_gfaa014-B20","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.18632\/oncotarget.7506","article-title":"A follow-up analysis of positron emission tomography\/computed tomography in detecting hidden malignancies at the time of diagnosis of membranous nephropathy","volume":"7","author":"Feng","year":"2016","journal-title":"Oncotarget"},{"key":"2021042619265242000_gfaa014-B21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021042619265242000_gfaa014-B22","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2005.08.020","article-title":"Idiopathic membranous nephropathy: outline and rationale of a treatment strategy","volume":"46","author":"Du Buf-Vereijken","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2021042619265242000_gfaa014-B23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ckj\/sfw152","article-title":"Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy","volume":"10","author":"Mathrani","year":"2017","journal-title":"Clin Kidney J"},{"key":"2021042619265242000_gfaa014-B24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","article-title":"Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations","volume":"72","author":"Cattran","year":"2007","journal-title":"Kidney Int"},{"key":"2021042619265242000_gfaa014-B25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"2021042619265242000_gfaa014-B26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","article-title":"Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide","volume":"2","author":"Ramachandran","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2021042619265242000_gfaa014-B27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide","volume":"50","author":"Branten","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2021042619265242000_gfaa014-B28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2021042619265242000_gfaa014-B29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1046\/j.1523-1755.1999.00675.x","article-title":"Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy","volume":"56","author":"Berg","year":"1999","journal-title":"Kidney Int"},{"key":"2021042619265242000_gfaa014-B30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2021042619265242000_gfaa014-B31","doi-asserted-by":"crossref","first-page":"e0142033","DOI":"10.1371\/journal.pone.0142033","article-title":"Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study","volume":"10","author":"van de Logt","year":"2015","journal-title":"PLoS One"},{"key":"2021042619265242000_gfaa014-B32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/ckj\/sfw045","article-title":"Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis","volume":"9","author":"Kittanamongkolchai","year":"2016","journal-title":"Clin Kidney J"},{"key":"2021042619265242000_gfaa014-B33","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"2021042619265242000_gfaa014-B34","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2\u2013year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B35","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000333068","article-title":"Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients","volume":"1","author":"Michel","year":"2011","journal-title":"Nephron Extra"},{"key":"2021042619265242000_gfaa014-B37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B39","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1056\/NEJM199206183262502","article-title":"Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases","volume":"326","author":"Feutren","year":"1992","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B40","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJMc1910393","article-title":"Rituximab or cyclosporine for membranous nephropathy","volume":"381","author":"Ponticelli","year":"2019","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B42","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"2021042619265242000_gfaa014-B43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"key":"2021042619265242000_gfaa014-B44","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B45","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipaseA2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"10","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"Proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"DeVriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B47","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021042619265242000_gfaa014-B48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ckj\/sfz127","article-title":"Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal","volume":"12","author":"Rojas-Rivera","year":"2019","journal-title":"Clin Kidney J"},{"key":"2021042619265242000_gfaa014-B49","article-title":"Membranous glomerulonephritis: a step forward in B-cell targeting therapy","author":"Dahan","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2021042619265242000_gfaa014-B50","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","author":"Barrett","year":"2019","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/5\/768\/37400206\/gfaa014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/5\/768\/37400206\/gfaa014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T23:04:58Z","timestamp":1619478298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/5\/768\/5811117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3,24]]},"published-print":{"date-parts":[[2021,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa014","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,3,24]]}}}